Yumanity To Reverse Merge With Kineta Two Years After Its Own Public Debut

06 Jun 2022

After its August 2020 reverse merger, neuroscience-focused Yumanity is calling it quits with two transactions: an asset sale to Janssen and a merger with private cancer immunotherapy firm Kineta.

Concept Image For Deals — Yumanity is reverse merging with Kineta, enabling the latter to go public • Source: Alamy

Less than two years after going public via a reverse merger with troubled cystic fibrosis company Proteostasis Therapeutics, Inc., Yumanity Therapeutics, Inc. is winding up its operations by selling off its lead clinical candidate and preclinical neuroscience pipeline to Johnson & Johnson and merging with Kineta, Inc. in a transaction that will confer Yumanity’s NASDAQ listing to the privately held cancer immunotherapy firm.

Upon close of the all-stock transaction announced 6 June, the resulting company will be named Kineta Inc., based in Seattle...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

24 Jul 2025

• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.